Nabriva Therapeutics AG PE Ratio 2015-2021 | NBRV

Current and historical p/e ratio for Nabriva Therapeutics AG (NBRV) from 2015 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Nabriva Therapeutics AG PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Nabriva Therapeutics AG PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 1.21 0.00
2021-06-30 1.35 $-1.03 0.00
2021-03-31 1.66 $-2.14 0.00
2020-12-31 2.42 $-4.11 0.00
2020-09-30 5.33 $-5.90 0.00
2020-06-30 6.75 $-9.20 0.00
2020-03-31 5.75 $-10.80 0.00
2019-12-31 13.20 $-11.20 0.00
2019-09-30 20.00 $-12.40 0.00
2019-06-30 24.30 $-19.00 0.00
2019-03-31 24.40 $-20.40 0.00
2018-12-31 14.60 $-21.10 0.00
2018-09-30 27.00 $-23.00 0.00
2018-06-30 34.80 $-20.60 0.00
2018-03-31 50.30 $-21.60 0.00
2017-12-31 59.80 $-23.60 0.00
2017-09-30 81.90 $-24.50 0.00
2017-06-30 104.80 $-24.50 0.00
2017-03-31 120.00 $-24.70 0.00
2016-12-31 59.60 $-25.50 0.00
2016-09-30 70.50 $-18.60 0.00
2016-06-30 75.00 $-12.00 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.587B $0.005B
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71